MT-228

• Description:

  MT-228 (BPN-0026709) is a selective and blood-brain barrier permeable non-muscle myosin II inhibitor. MT-228 markedly improves tolerability by selectively targeting NMIIB (KI = 1.5 μM) over CMII (KI = 17 μM), and the sequence of SmMll MD is 83.6% identical to that of NMllB. MT-228 shows long-lasting efficacy in animal models of stimulant use disorder[1].

• Product Name Alternative:

  BPN-0026709

• UNSPSC:

  12352005

• Target:

  Myosin

• Related Pathways:

  Cytoskeleton

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Purity:

  99.9

• Smiles:

  O=C1[C@@]2 (O) C (N (C3=CC (OC) =NC=C3) CC2) =NC4=C1C=C (C) C (C) =C4

• Molecular Formula:

  C19H19N3O3

• Molecular Weight:

  337.37

• References & Citations:

  [1]Radnai L, et al. Development of Clinically Viable Non-Muscle Myosin II Small Molecule Inhibitors with Broad Therapeutic Potential. bioRxiv [Preprint]. 2024 Oct 12:2024.10.07.617018.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  2404652-24-8